Amneal Pharmaceuticals price target raised to $9 from $7 at Truist

Truist analyst Les Sulewski raised the firm’s price target on Amneal Pharmaceuticals to $9 from $7 and keeps a Buy rating on the shares after its Q1 earnings beat. The stock initially fell as investors digested the company’s opioid settlement, though the firm sees the company “firing on all cylinders” with all three of its segments posting double-digit growth, the analyst tells investors in a research note. Truist adds that it still sees upside to Amneal’s reaffirmed guidance, appreciating the company’s long-term optionality from new product launches and compounded growth on-top of its Parkinson’s franchise.